U.S. FDA Approves CARVYKTI ™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., February 28, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.1 The approval is based on data from the pivotal CARTITUDE-1 study, which included patients who had received a median of six prior treatment regimens (range, 3-18), and had previously rec...
Source: Johnson and Johnson - March 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Johnson & Johnson Statement on Nationwide Opioid Settlement Agreement
NEW BRUNSWICK, N.J., February 25, 2022 – Johnson & Johnson and its U.S.-based Janssen Pharmaceutical Companies (collectively, the “Company”) today confirmed there is sufficient level of participation to move forward with the nationwide settlement agreement to resolve opioid-related claims and litigation by states, cities, counties, and other subdivisions in the United States. As previously announced on July 21, 2021, the Company will contribute up to $5 billion to the nationwide settlement, which is designed to directly support state and local efforts to make meaningful progress in addressing the opioid crisis in...
Source: Johnson and Johnson - February 25, 2022 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson Names Darius Adamczyk, Chairman and Chief Executive Officer of Honeywell, to its Board of Directors
New Brunswick, NJ (February 15, 2022) – Johnson & Johnson announced today that Darius Adamczyk, Chairman and Chief Executive Officer of Honeywell, has been appointed to its Board of Directors. “I am delighted to welcome Darius to Johnson & Johnson’s Board of Directors,” said Alex Gorsky, Executive Chairman, Johnson & Johnson. “Darius is an accomplished global leader with decades of experience and a track record of growing businesses. He is also a champion of sustainability and investments in innovation to improve the lives of people around the world. Darius’s extensive knowledge of numerous business...
Source: Johnson and Johnson - February 15, 2022 Category: Pharmaceuticals Tags: Our Company Source Type: news
Janssen Presents New Data Demonstrating the Combination of Niraparib and Abiraterone Acetate Plus Prednisone Significantly Improved Radiographic Progression-Free Survival as a First-Line Therapy in Patients with HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced initial results from the Phase 3 MAGNITUDE study evaluating the investigational use of niraparib, a selective poly-ADP ribose polymerase (PARP) inhibitor, in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) with or without specific homologous recombination repair (HRR) gene alterations. At the final analysis for radiographic progression-free survival (rPFS), the treatment combination of niraparib and abiraterone acetate plus prednisone de...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
New ERLEADA ® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. The...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Johnson & Johnson to Participate in the Raymond James 43rd Annual Institutional Investors Conference
New Brunswick, NJ (February 9th, 2022) - Johnson & Johnson (NYSE: JNJ) will participate in the Raymond James 43rd Annual Institutional Investors Conference on Tuesday, March 8th. Joseph J. Wolk, Executive Vice President and Chief Financial Officer, will represent the Company in a session scheduled at 1:05 p.m. (Eastern Time). This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.A webcast replay will be available approximately 48-hrs after the live webcast. (Source: Johnson and Johnson)
Source: Johnson and Johnson - February 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Johnson & Johnson to Participate in the Cowen 42nd Annual Health Care Virtual Conference
New Brunswick, NJ (February 7th, 2022) -- Johnson & Johnson (NYSE: JNJ) will participate in the Cowen 42nd Annual Health Care Virtual Conference on Monday, March 7th. Mathai Mammen, Executive Vice President, Pharmaceuticals R&D will represent the Company in a session scheduled at 9:10 a.m. (Eastern Time). This conference call will be available to investors and other interested parties by visit the Johnson & Johnson website at www.investor.jnj.com.A webcast and podcast replay will be available approximately 48 hours after the live webcast. (Source: Johnson and Johnson)
Source: Johnson and Johnson - February 7, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Johnson & Johnson to Participate in the Cowen 42nd Annual Health Care Virtual Conference
New Brunswick, NJ (February 7th, 2022) -- Johnson & Johnson (NYSE: JNJ) will participate in the Cowen 42nd Annual Health Care Virtual Conference on Monday, March 7th. Mathai Mammen, Executive Vice President, Pharmaceuticals R&D will represent the Company in a session scheduled at 9:10 a.m. (Eastern Time). This conference call will be available to investors and other interested parties by visit the Johnson & Johnson website at www.investor.jnj.com.A webcast and podcast replay will be available approximately 48 hours after the live webcast. ### (Source: Johnson and Johnson)
Source: Johnson and Johnson - February 7, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Johnson & Johnson Statement on Federally Recognized Tribes Opioid Settlement Agreement
NEW BRUNSWICK, NJ, February 1, 2022 - Johnson & Johnson (the Company) and its U.S.-based Janssen Pharmaceutical Companies today announced a settlement agreement with the federally recognized Tribes resolving their opioid-related claims against the Company. The $150 million settlement with the Tribes is consistent with the framework of the previously announced nationwide opioid settlement agreement. The dollar amount to be received by the Tribes has been deducted from the all-in settlement amount. This settlement is not an admission of any liability or wrongdoing and the Company will continue to defend against any litig...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Source Type: news
U.S. FDA Approves CABENUVA (rilpivirine and cabotegravir) for Use Every Two Months, Expanding the Label of the First and Only Long-Acting HIV Treatment
TITUSVILLE, N.J., February 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved an expanded label for CABENUVA (rilpivirine and cabotegravir) to be administered every two months for the treatment of HIV-1 in virologically suppressed adults (HIV-1 RNA less than 50 copies per milliliter [c/ml]) on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either rilpivirine or cabotegravir. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janss...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
Raritan, NJ, Feb. 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 17 presentations will be featured at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place in San Francisco and virtually from February 17-19. Building on its long-term leadership in prostate cancer, Janssen is committed to advancing innovative treatments and transforming patient experiences, while focusing on research that may drive better outcomes for people across the genitourinary cancer spectrum. Data to be presented include Phase 3 results for the selective ...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Johnson & Johnson to Participate in Citi ’s 2022 Virtual Healthcare Conference
New Brunswick, NJ (January 27th, 2022) - Johnson & Johnson (NYSE: JNJ) will participate in Citi’s 2022 Virtual Healthcare Conference on Wednesday, February 23rd, Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices will represent the Company in a session scheduled at 11:00 a.m. (Eastern Time). This conference call will be available to investors and other interested parties by visit the Johnson & Johnson website at www.investor.jnj.com. A webcast and podcast replay will be available approximately 48 hours after the live webcast. (Source: Johnson and Johnson)
Source: Johnson and Johnson - January 27, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Johnson & Johnson Marks More Than 2 Billion Doses of Medicine Donated to Date to Help Combat Intestinal Worms
NEW BRUNSWICK, N.J., January 27, 2022 – In advance of World Neglected Tropical Diseases (NTD) Day on January 30, Johnson & Johnson is pleased to announce it has now donated a total of more than 2 billion doses of mebendazole, its medicine to treat intestinal worm infections, to people in need in more than 50 resource-limited countries worldwide. This marks the latest achievement in Johnson & Johnson’s longstanding donation program aimed at helping children, who are especially vulnerable to intestinal worms, live healthier lives. “More than fifteen years ago, Johnson & Johnson committed to address the thre...
Source: Johnson and Johnson - January 27, 2022 Category: Pharmaceuticals Source Type: news
A Newly Published Network Meta-Analysis (NMA) Found TREMFYA ® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
Conclusions (i.e., comparable) are based on an overlap of pairwise 95 percent credible intervals.1c. PASI 90 is defined as at least 90 percent improvement from baseline in the PASI score. The PASI score grades the amount of surface area on each body region that is covered by PsO plaques and the severity of plaques for their redness, thickness, and scaliness.13 PASI 90 was not a controlled endpoint in DISCOVER-1 or -2.8,9d. TREMFYA q4w dosing is not currently FDA-approved.2e. The PsA-modified vdH-S score combines erosion and joint space narrowing scores derived from radiographs of joints in body regions impacted by PsA.14 T...
Source: Johnson and Johnson - January 26, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Johnson & Johnson Reports Q4 and Full-Year 2021 Results
New Brunswick, N.J. (January 25, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2021. “Our 2021 performance reflects continued strength across all segments of our business. Guided by Our Credo, I am honored to assume the role of CEO, leading our global teams in continuing our work to deliver life-changing solutions to consumers, patients, and health care providers” said Joaquin Duato, Chief Executive Officer. “Given our strong results, financial profile, and innovative pipeline we are well positioned for success in 2022 and beyond.” OVERALL FINANCIAL RESULTS
...
Source: Johnson and Johnson - January 25, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news
